Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Neurocrine Projected to file IND for CRF Antagonist Compound in 2016

Source Link:: http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTA3MzI3NjMmc3Vic2lkPTU3&ListAll=1&sXBRL=1

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

NBIX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Neurocrine is investigating multiple CRF antagonist compounds in preclinical evaluations and anticipate filing an IND for at least 1 in 2016.

http://phoenix.corpo...

Additional Relevant Details Update on 14 Feb 2017: The Company has submitted an Investigational New Drug application with the FDA for its CRF receptor antagonist NBI-74788 to treat patients with classic congenital adrenal hyperplasia (CAH).

http://phoenix.corpo...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Feb 14, 2017

Occurred Source:

http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=2246000

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords International New Drug Application, Crf Antagonist Compound, Corticotropin-releasing Factor, Congenital Adrenal Hyperplasia